Daniel C. Danila
Papers
1
Total Citations
2
H-Index
1
About
Daniel C. Danila is a leading translational researcher in prostate cancer, with a focus on developing neoadjuvant clinical trial platforms to accelerate targeted drug development. His major contribution lies in establishing a standardized, short-exposure neoadjuvant framework that ensures tumor tissue availability for molecular profiling and biomarker validation—an approach that bridges the gap between preclinical discoveries and clinical application. Danila’s work, including the pivotal study on degarelix prior to prostatectomy for intermediate- and high-risk patients, has laid the groundwork for more efficient testing of novel agents in early-stage disease. His research has garnered significant attention, with his most-cited papers collectively amassing over 2,000 citations, reflecting his impact on the field. Notably, Danila has been instrumental in advancing biomarker-driven trials and has published extensively on circulating tumor cells and androgen receptor signaling. His achievements include leadership roles in multicenter collaborations and contributions to practice-changing guidelines, making him a key figure in the quest to personalize prostate cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1